ArticleChinese medicine2026
Jinshui Chenfei formula alleviates SiO
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundJinshui Chenfei Formula (JCF), a proprietary Chinese medicinal prescription, has demonstrated remarkable therapeutic efficacy in treating pneumoconiosis patients. However, the precise mechanisms remain to be elucidated. This study aimed to investigate how JCF counteracts M2 macrophage polarization and thereby attenuates SiO
methodsThis study aimed to observe the effects of JCF on collagen deposition and macrophage M2 polarization in silicotic lungs induced by silica at 14 days, 28 days, and 42 days in rats. The active fraction of JCF was isolated and extracted using macroporous resin. Subsequently, RNA-seq was performed to predict the potential mechanism involved in the improvement of IL4-induced bone marrow-derived macrophages (BMDMs) by JCF. Finally, the targets of the active fraction of JCF were identified by the DARTS experiment. The underlying mechanisms were elucidated by combining siRNA and plasmid overexpression techniques.
resultsJCF significantly improved pulmonary function and pathological remodeling in silicosis rats across different time points, reduced collagen deposition in lung tissues, and downregulated the expression of M2 macrophage markers. JCF5, the active fraction of JCF, potently inhibited IL4-induced M2 polarization of bone marrow-derived macrophages (BMDMs). RNA-seq identified 96 differential expressed genes (DEGs) associated with M2 polarization and JCF5 treatment, which enriched signaling pathways such as JAK/STAT. In vitro experiment confirmed that JCF5 markedly reduced STAT6 phosphorylation. Drug affinity responsive target stability (DARTS) assays revealed that JCF5 suppress STAT6 activation by down-regulating Grb2, siRNA-mediated Grb2 knockdown potently reduced IL-4-induced M2 macrophages, whereas Grb2 overexpression significantly alleviated the inhibitory effects of JCF5 on STAT6 activation and M2 polarization. Further, Hesperidin is the main active ingredient verified by molecular docking and cell function assays.
conclusionJCF downregulate STAT6 activation by regulating Grb2, thereby inhibit M2 polarization of macrophage and improve pulmonary fibrosis in silicotic rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.